Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Drug
AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry
Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...
Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study
US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase...
Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC
Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01...
Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH
US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results...
Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo
China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US...
GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug...
Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939
China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...
SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024
SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...
Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the...
Sichuan Kelun-Biotech Receives NMPA Clearance for SKB501 Clinical Trial in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...
Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...
Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH
US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced favorable interim analysis results...
GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study
China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...
Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment
Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the dosing of the first patient...
MicroPort Scientific Corp.’s BonaFire Receives NMPA Approval as First Whole-Body MRI Safety Pacing Electrode Lead
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...
Base Therapeutics’ NK510 Receives US FDA Clearance for Advanced Solid Tumor Studies
Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug...
GSK’s Arexvy Receives MHLW Approval for Expanded RSV Indication in Japan
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that Japan’s Ministry of Health, Labour...